HCV Treatment
AASLD 2011: HCV Direct-Acting Antivirals Boost Interferon Response Rates
- Details
- Category: HCV Treatment
- Published on Tuesday, 15 November 2011 00:00
- Written by Liz Highleyman
Several studies at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2011) last week in San Francisco showed that adding experimental direct-acting antiviral (DAA) agents to pegylated interferon plus ribavirin increases virological response rates for people with chronic hepatitis C.
BI 201335 Performs Well with Standard Therapy
TMC435 + Pegylated Interferon/Ribavirin
PSI-7977 + Pegylated Interferon/Ribavirin
12-week Daclatasvir + Pegylated Interferon/Ribavirin
Danoprevir + Pegylated Interferon/Ribavirin
AASLD 2011: Do Hepatitis C Patients with Cirrhosis Benefit from Adding Telaprevir?
- Details
- Category: HCV Treatment
- Published on Tuesday, 15 November 2011 00:00
- Written by Liz Highleyman
Adding telaprevir to pegylated interferon/ribavirin increased the likelihood of a cure for genotype 1 chronic hepatitis C patients with liver cirrhosis in the REALIZE trial, according to data presented at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2011) last week in San Francisco.
AASLD 2011: Telaprevir Improves Hepatitis C Treatment Response for HIV/HCV Coinfected People
- Details
- Category: HCV Treatment
- Published on Tuesday, 08 November 2011 00:00
- Written by Liz Highleyman
Adding the hepatitis C virus (HCV) protease inhibitor telaprevir (Incivek) to pegylated interferon plus ribavirin increased virological response rates at 24 weeks for HIV/HCV coinfected patients, researchers reported at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2011) this week in San Francisco.
AASLD 2011: Adding Tenofovir to Entecavir Offers No Additional Benefit for Hepatitis B Patients
- Details
- Category: HCV Treatment
- Published on Tuesday, 15 November 2011 00:00
- Written by Liz Highleyman
Dual therapy using entecavir (Baraclude) plus tenofovir (Viread) did not work better than entecavir alone in a 3-year study of previously untreated chronic hepatitis B patients, according to a presentation at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2011) last week in San Francisco.
AASLD 2011: New NS5A Inhibitor PPI-461 Shows Promising Safety and Efficacy in Brief Study
- Details
- Category: HCV Treatment
- Published on Tuesday, 08 November 2011 00:00
- Written by Presidio
Presidio's hepatitis C virus (HCV) NS5A inhibitor candidate PPI-461 demonstrated rapid and potent antiviral activity in a 3-day study, but resistance may be a problem, according to a study presented at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2011) this week in San Francisco.
Web Design and Development by